Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,138 public posts
Filter results
Bayer Starts Phase I Study With Novel Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer Prostate cancer is the second most commonly diagnosed cancer in men1, with less than three years median survival among metastatic patients, who have developed
castration
-resistance2
is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer Prostate cancer is the second most commonly diagnosed cancer in men1, with less than three years median survival among metastatic patients, who have developed
castration
-resistance2
God_Loves_Me
in
Advanced Prostate Cancer
2 months ago
new immune therapy phase 1-2 trial: targeting NK cells
The first patient with metastatic
castration
-resistant prostate cancer (mCRPC) has been dosed in the phase 1/2 CaRe PC trial (NCT06056791) evaluating INKmune, a biologic therapy https://www.targetedonc.com/view/first-patient-dosed-with-inkmune-therapy-in-phase-1-2-trial-for-mcrpc
The first patient with metastatic
castration
-resistant prostate cancer (mCRPC) has been dosed in the phase 1/2 CaRe PC trial (NCT06056791) evaluating INKmune, a biologic therapy https://www.targetedonc.com/view/first-patient-dosed-with-inkmune-therapy-in-phase-1-2-trial-for-mcrpc
Maxone73
in
Advanced Prostate Cancer
7 months ago
SNMMI 2024: 225Ac-PSMA/177Lu-PSMA Tandem Therapy for Metastatic Castration-Resistant Prostate Cancer
Fuad Novruzov presented the results of a prospective phase 3 randomized study from Azerbaijan evaluating 225Ac-PSMA + 177Lu-PSMA tandem therapy for metastatic
castration
-resistant prostate cancer (mCRPC).
Fuad Novruzov presented the results of a prospective phase 3 randomized study from Azerbaijan evaluating 225Ac-PSMA + 177Lu-PSMA tandem therapy for metastatic
castration
-resistant prostate cancer (mCRPC).
God_Loves_Me
in
Advanced Prostate Cancer
1 month ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
PARP inhibitor Olaparib, phase 3 study findings (PROpel)
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/152812-olaparib-plus-abiraterone-versus-placebo-plus-abiraterone-in-metastatic-
castration
-resistant-prostate-cancer-propel-final-prespecified-overall-survival-results-of-a-randomised-double-blind-phase-3-trial-beyond-the-abstract.html
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/152812-olaparib-plus-abiraterone-versus-placebo-plus-abiraterone-in-metastatic-
castration
-resistant-prostate-cancer-propel-final-prespecified-overall-survival-results-of-a-randomised-double-blind-phase-3-trial-beyond-the-abstract.html
Maxone73
in
Advanced Prostate Cancer
20 days ago
Currently in phase 1 but promising: Bispecific Antibody Programs and IL-12 Cytokine, XmAb662
early results are positive on solid tumors, including prostate https://www.pharmaceutical-technology.com/data-insights/xmab-662-xencor-metastatic-
castration
-resistant-prostate-cancer-mcrpc-likelihood-of-approval-2/ Thanks mhamle01 !!
early results are positive on solid tumors, including prostate https://www.pharmaceutical-technology.com/data-insights/xmab-662-xencor-metastatic-
castration
-resistant-prostate-cancer-mcrpc-likelihood-of-approval-2/ Thanks mhamle01 !!
Maxone73
in
Advanced Prostate Cancer
7 months ago
Bone metastasis drug looks good: phase 2 trial of PT-112 gave good results
https://www.biospace.com/article/releases/promontory-therapeutics-completes-enrollment-of-phase-2-trial-of-pt-112-in-late-line-patients-with-metastatic-
castration
-resistant-prostate-cancer/ NPfisherman is the science coming???? 😀
https://www.biospace.com/article/releases/promontory-therapeutics-completes-enrollment-of-phase-2-trial-of-pt-112-in-late-line-patients-with-metastatic-
castration
-resistant-prostate-cancer/ NPfisherman is the science coming???? 😀
Maxone73
in
Advanced Prostate Cancer
4 months ago
ok, last one before Christmas: AsiDNA (DT-01)
promising multi cancer Dbait (double-strand breaks (DSBs) family https://www.labiotech.eu/trends-news/onxeo-study-prostate-cancer-drug/ https://www.pharmaceutical-technology.com/data-insights/asidna-valerio-therapeutics-metastatic-
castration
-resistant-prostate-cancer-mcrpc-likelihood-of-approval-2/
promising multi cancer Dbait (double-strand breaks (DSBs) family https://www.labiotech.eu/trends-news/onxeo-study-prostate-cancer-drug/ https://www.pharmaceutical-technology.com/data-insights/asidna-valerio-therapeutics-metastatic-
castration
-resistant-prostate-cancer-mcrpc-likelihood-of-approval-2/
Maxone73
in
Advanced Prostate Cancer
7 months ago
androgen receptor inhibitor for nmCRPC
So if you become
castration
resistant. Your PCa will grow without androgen. Your MO will recommend an androgen receptor inhibitor. Why bother inhibiting PCa androgen receptors if it can survive without androgen?? Confused.
So if you become
castration
resistant. Your PCa will grow without androgen. Your MO will recommend an androgen receptor inhibitor. Why bother inhibiting PCa androgen receptors if it can survive without androgen?? Confused.
Hidden
in
Advanced Prostate Cancer
1 year ago
Gout drug febuxostat may be useful as repurposed drug for CRPC
The effects of febuxostat and allopurinol
castration
–resistant prostate cancer cells using CD44 as an indicator: possibility for the drug repurposing of febuxostat in
castration
–resistant prostate cancer Authors: Yasuhiro Suzuki1, et al.
The effects of febuxostat and allopurinol
castration
–resistant prostate cancer cells using CD44 as an indicator: possibility for the drug repurposing of febuxostat in
castration
–resistant prostate cancer Authors: Yasuhiro Suzuki1, et al.
Graham49
in
Advanced Prostate Cancer
8 months ago
FDA Greenlights Phase 2/3 Trial of KPG-121/Abiraterone in mCRPC
A clinical trial to evaluate the combination of a new drug called KPG-121 with abiraterone acetate (Zytiga) for treating metastatic
castration
-resistant prostate cancer (mCRPC) as a first-line therapy has been approved by the FDA.
A clinical trial to evaluate the combination of a new drug called KPG-121 with abiraterone acetate (Zytiga) for treating metastatic
castration
-resistant prostate cancer (mCRPC) as a first-line therapy has been approved by the FDA.
God_Loves_Me
in
Advanced Prostate Cancer
1 month ago
promising against soft tissue and bone metastasis: AMG 509
https://www.urotoday.com/conference-highlights/esmo-2023/esmo-2023-prostate-cancer/147455-esmo-2023-steap1-x-cd3-xmab-2-1-immune-therapy-in-patients-with-metastatic-
castration
-resistant-prostate-cancer-mcrpc-interim-results-phase-1-amg-509-xaluritamig.html
https://www.urotoday.com/conference-highlights/esmo-2023/esmo-2023-prostate-cancer/147455-esmo-2023-steap1-x-cd3-xmab-2-1-immune-therapy-in-patients-with-metastatic-
castration
-resistant-prostate-cancer-mcrpc-interim-results-phase-1-amg-509-xaluritamig.html
Maxone73
in
Advanced Prostate Cancer
7 months ago
CELC-G-201 Phase 1b/2 clinical trial: gedatolisib plus darolutamide in mCRPC
https://www.biospace.com/article/releases/celcuity-announces-first-patient-dosed-in-phase-1b-2-celc-g-201-clinical-trial-of-gedatolisib-for-the-treatment-of-metastatic-
castration
-resistant-prostate-cancer/
https://www.biospace.com/article/releases/celcuity-announces-first-patient-dosed-in-phase-1b-2-celc-g-201-clinical-trial-of-gedatolisib-for-the-treatment-of-metastatic-
castration
-resistant-prostate-cancer/
Maxone73
in
Advanced Prostate Cancer
5 months ago
Metastatic Castration-Resistant Prostate Cancer Pipeline: 75+ companies with 75+ pipeline drugs are involved
https://www.digitaljournal.com/pr/news/getnews/metastatic-
castration
-resistant-prostate-cancer-pipeline-clinical-trials-studies-emerging-drugs-mergers-and-acquisition-licensing-agreements-collaborations-and-latest-news-2023-updated- Let's hope!!
https://www.digitaljournal.com/pr/news/getnews/metastatic-
castration
-resistant-prostate-cancer-pipeline-clinical-trials-studies-emerging-drugs-mergers-and-acquisition-licensing-agreements-collaborations-and-latest-news-2023-updated- Let's hope!!
Maxone73
in
Advanced Prostate Cancer
8 months ago
News about phase 1 trial for mCRPC: BMS-986365
Plenty of hopefully good news at ASCO 2024 on the 25th of Jan "First disclosure of clinical outcomes from Phase 1 trial with BMS-986365 (CC-94676), the company’s first androgen receptor ligand-directed degrader in solid tumors from its targeted protein degradation platform, in metastatic
castration
-resistant
Plenty of hopefully good news at ASCO 2024 on the 25th of Jan "First disclosure of clinical outcomes from Phase 1 trial with BMS-986365 (CC-94676), the company’s first androgen receptor ligand-directed degrader in solid tumors from its targeted protein degradation platform, in metastatic
castration
-resistant
Maxone73
in
Advanced Prostate Cancer
6 months ago
New therapy (I hope I am not repeating myself)
prostate cancer (mCSPC) and metastatic
castration
-resistant prostate cancer (mCRPC), according to interim results from a phase 1/2 clinical trial (NCT04633252) announced by PDS Biotech, the developer of the therapy, in a news release.
prostate cancer (mCSPC) and metastatic
castration
-resistant prostate cancer (mCRPC), according to interim results from a phase 1/2 clinical trial (NCT04633252) announced by PDS Biotech, the developer of the therapy, in a news release.
Maxone73
in
Advanced Prostate Cancer
9 months ago
Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with mCRPC
https://www.biospace.com/article/releases/bioxcel-therapeutics-reports-positive-overall-survival-results-from-single-arm-open-label-phase-2-trial-of-bxcl701-in-patients-with-metastatic-
castration
-resistant-prostate-cancer-mcrpc-of-adenocarcinoma-phenotype/
https://www.biospace.com/article/releases/bioxcel-therapeutics-reports-positive-overall-survival-results-from-single-arm-open-label-phase-2-trial-of-bxcl701-in-patients-with-metastatic-
castration
-resistant-prostate-cancer-mcrpc-of-adenocarcinoma-phenotype/
Maxone73
in
Advanced Prostate Cancer
8 months ago
Janux immunotherapy drug (JANX007) for mCRPC
news-details/2024/Janux-Announces-Encouraging-Safety-and-Efficacy-Data-in-Ongoing-Dose-Escalation-Trials-for-PSMAxCD3-TRACTr-JANX007-in-mCRPC-and-EGFRxCD3-TRACTr-JANX008-in-Solid-Tumors/default.aspx "Analysts were particularly impressed by the results Janux shared from treated participants with metastatic,
castration
-resistant
news-details/2024/Janux-Announces-Encouraging-Safety-and-Efficacy-Data-in-Ongoing-Dose-Escalation-Trials-for-PSMAxCD3-TRACTr-JANX007-in-mCRPC-and-EGFRxCD3-TRACTr-JANX008-in-Solid-Tumors/default.aspx "Analysts were particularly impressed by the results Janux shared from treated participants with metastatic,
castration
-resistant
nyc_son
in
Advanced Prostate Cancer
5 months ago
Constipation is a known issue with the Orgovyx
If I have to change meds to alleviate this, I'm leaning toward upping my dose of Estradiol to
castration
-level rather than trying another ADT. But I'd prefer to stay or Orgovyx for the time being because it has worked so well so far.
If I have to change meds to alleviate this, I'm leaning toward upping my dose of Estradiol to
castration
-level rather than trying another ADT. But I'd prefer to stay or Orgovyx for the time being because it has worked so well so far.
NewPotatoCaboose
in
Advanced Prostate Cancer
3 months ago
Stopping Firmagon if castration resistant
This may seem like a daft question but what is the position with continuing or stopping Firmagon when you're
castration
resistant? Is its purpose to control the spread of testosterone that would otherwise make the cancer even worse? Thanks
This may seem like a daft question but what is the position with continuing or stopping Firmagon when you're
castration
resistant? Is its purpose to control the spread of testosterone that would otherwise make the cancer even worse? Thanks
Finlay66
in
Advanced Prostate Cancer
1 year ago
And more ASCO GU 2024 phase 3 trial
Data will be presented at ASCO GU 2024 but looks promising "In combination with immunotherapy, Cabometyx is delivering long-term survival benefits today for people living with renal cell carcinoma worldwide, while also showcasing future potential in metastatic
castration
-resistant prostate cancer, an
Data will be presented at ASCO GU 2024 but looks promising "In combination with immunotherapy, Cabometyx is delivering long-term survival benefits today for people living with renal cell carcinoma worldwide, while also showcasing future potential in metastatic
castration
-resistant prostate cancer, an
Maxone73
in
Advanced Prostate Cancer
6 months ago
1
...
4
5
6
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1015 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest